News
Feed
Events
Feed
News
+ Events
Feed

Kintor Pharmaceutical

  • Land Hong Kong

Aktuelle News

29 August 2023

03:57 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights

12 Mai 2023

03:49 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

31 März 2023

04:10 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

29 März 2023

05:05 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China

21 März 2023

08:25 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma’s KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

13 Februar 2023

02:59 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

2 Dezember 2022

03:34 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met

24 November 2022

02:48 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use

10 November 2022

03:09 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715

27 Oktober 2022

11:58 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

30 August 2022

05:13 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented

27 September 2021

04:37 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces Brazil’s ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients

9 September 2021

04:09 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met

28 Juli 2021

10:13 Corporate EN

Kintor Pharmaceutical

Corporate
EN

GT20029’s Successful Dosing of First Batch of Subjects in China

16 Juli 2021

08:44 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

17 Juni 2021

11:17 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Proxalutamide’s Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

11 Januar 2021

02:55 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor’s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Re-sults in Treatment of Male and Female Patients

14 Dezember 2020

03:42 Corporate EN

Kintor Pharmaceutical

Corporate
EN

Kintor Proxalutamide’s COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates

Anstehende Events

Keine Events gefunden